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Abstract
Background: Venous thromboembolism (VTE) is a well-recognised and life-threatening complication in patients
with cancer. However, the precise risk of VTE in hospitalised cancer patients in England has not been previously
reported.
Methods: We conducted a cohort study using linked Hospital Episodes Statistics and Office for National Statistics
mortality data. We determined the risk of VTE separately for 24 cancer sites following first hospitalisation for cancer
(index date) and how this varied by age, proximity from hospital admission, administration of chemotherapy and
calendar time.
Results: Between 1998 and 2012, 3,558,660 patients were hospitalised for cancer. The cancer sites with the highest
risk of VTE during initial hospitalisation for cancer were pancreatic (4.9 %), ovarian (4 %) and liver (3.8 %). The three
cancer sites with the highest risk of first VTE event within 6 months from discharge were pancreatic (3.7 %), oesophagus
(3 %) and stomach (2.8 %). For most cancers, the risk of VTE within 6 months from discharge was higher amongst
patients who underwent chemotherapy compared to those who did not. The impact of age on risk of VTE varied
considerably between cancer sites.
Conclusions: The risk of VTE amongst patients hospitalised for cancer varies greatly by cancer site, age, proximity
from hospital admission, and chemotherapy administration.
Keyword: Cancer, Venous thrombosis, Hospitalisation, Epidemiology, Chemotherapy
Background
Venous thromboembolism (VTE) is responsible for ap-
proximately 25,000 deaths each year in the UK, and it is
well established that patients with cancer are at higher
risk of VTE compared to the general population [1–3].
The estimated annual incidence of VTE in the cancer
population is 1.3 %, and the risk of death is higher for
cancer patients with VTE than for those without [4–8].
Given the ageing population and increased early diagnosis,
more people are living with cancer in the UK than ever
before [9]. Therefore, the prevention of a potentially fatal
cancer-associated VTE amongst patients is of paramount
importance. Furthermore, the long-term consequences of
VTE such as post-thrombotic syndrome (PTS) are more
of an issue now as people with cancer are living long
enough now to develop them. The cost to the NHS for
management of PTS is significant and covered in the
Department of Health enquiring into VTE [1].
Current UK guidelines, published by the National In-
stitute for Health and Care Excellence (NICE), recom-
mend prophylaxis for VTE for cancer patients admitted
to hospital, but only routinely to those hospitalised for 3
or more days or who are expected to have ongoing re-
duced mobility [10]. Prophylaxis is cheap and highly ef-
fective (around 50 to 70 % reduction) [11, 12]; however,
to prevent unnecessary harm from thromboprophylaxis
and its associated adverse effects, careful consideration
must be given to identify patients who are most at risk
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Previous studies and a recent report from the Centers
for Disease Control and Prevention confirm hospitalisa-
tion is an important risk factor for VTE and emphasise
the need for greater awareness of VTE risks and imple-
mentation of preventative measures in hospital [13, 14].
To date, a limited number of hospital-based studies in pa-
tients with cancer (outside of the UK only) have been con-
ducted, and the majority of studies did not determine the
risk of VTE following discharge [15–18]. Of the two that
did, one study was limited to a select patient group and
the other did not determine how the risk of re-admission
for VTE varies by potential risk factors [15, 16].
There is therefore a need for a hospital-based cohort
study in patients with cancer in England to determine con-
temporary and precise estimates of the risk of VTE, taking
into account risk factors such as age, cancer site, proximity
from admission and chemotherapy administration. Such
risk stratification could be used to inform future clinical
guidelines and optimise the use of prophylactic anticoagu-
lation when patients are admitted to hospital with cancer.
This study uses the English Hospital Episode Statistics
(HES) and linked Office for National Statistics (ONS)
death certificate data to determine the risk of VTE in
hospitalised cancer patients, during admission and post-
discharge, and stratified by risk factors.
Methods
Data source and patients
We conducted a cohort study using the Hospital Episode
Statistics (HES) database, which contains details on all in-
patient (except accident and emergency) and day case ad-
missions to English NHS hospitals from 1989. More than
12 million admission records are added each year [19]. The
database is managed by the Health and Social Care Infor-
mation Centre and contains data on hospitalisations, which
are broken down into periods of care seen by consultants
(episodes). The primary diagnosis (the main reason the pa-
tient is receiving care) per episode is indicated along with
all secondary diagnoses (any relevant comorbidities and
illnesses acquired whilst in hospital). A diagnosis is coded
using the ICD-10 (International Classification of Diseases,
10th revision), and all procedures which take place during
the admission are coded using the OPCS-4 (Office of
Population, Censuses and Surveys’ classification of surgical
operations and procedures, fourth revision). HES is linked
to the ONS death registry which provides the date of death
for all deceased patients.
We selected patients who had a first cancer diagnosis
recorded in HES (ICD-10 Chapter II, C00-C97, excluding
non-melanoma skin cancer) between 1 January 1998 and
31 October 2012, as this was the period the HES data
were available for at the time of writing. Patients who had
a VTE event were identified. Patients were excluded if:
 Under 18 years of age at first cancer diagnosis
 Had a VTE diagnosis in a hospital admission prior
to the cancer admission
Data were analysed separately for the 24 most common
cancer sites (based on 2007 UK incidence data). Cancer
sites not included within these were categorised as ‘Other’.
‘Unknown primary’ site consisted of metastatic cancers
with no known primary cancer site (C77–C80). Cancer
site classification was based on the first occurring cancer,
and the corresponding date was assumed to be the date of
diagnosis (termed index date from this point onwards).
Ethical approval was given by the ONS for this study (ref-
erence number RU863/NIC-165667-FH1W1).
VTE event
For the cancer patients, a VTE diagnosis was defined as
(i) having a hospital admission for pulmonary embolism
(ICD-10, I26) or venous thrombosis (ICD-10, I80, I81 or
I82), (ii) a diagnosis with one of the above codes during
a hospital admission for another reason and (iii) having
one of the above codes as underlying cause of death. The
first VTE event concurrent with or following the index
date was selected as the outcome of interest.
Chemotherapy
Patients receiving inpatient therapy were identified using
OPCS-4 codes for chemotherapy (X72.1, X72.2, X72.3
and X73.1).
Statistical methods
The risk of VTE was stratified by timing of the first VTE
event, that is, whether the event occurred during the same
hospitalisation as the index date or as re-admission in the
6 months following discharge, for all 24 cancers sites. Fur-
ther stratification by age-group (<60, 60–80 and >80 years)
was performed for the four most commonly diagnosed
cancers in the UK (breast, lung, bowel and prostate), those
found to be at high risk of VTE (according to our data)
and all cancers combined. The relative risk of first VTE as
a re-admission within 6 months from discharge amongst
those who had a record of chemotherapy compared to
those who did not was determined using logistic regres-
sion, for all cancer sites.
Trends in VTE risk over time (assigning patients to year
of index date) were investigated for the four most com-
monly diagnosed cancers. Patients whose first VTE event
was concurrent with their index date were removed from
this analysis to ensure the VTE event was subsequent to
the cancer diagnosis. Patients whose index date was in
2012 were also excluded from this part of the analysis as
data were not available for the full calendar year. To
control for differing length of hospital stay (a marker of
cancer severity), we repeated the analysis stratified by
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short-term (<3 days) and prolonged stay (≥3 days). This
cutoff was chosen according to NICE VTE guidelines
(NICE guidelines, 2010). We also conducted a sensitiv-
ity analysis to determine if trends for the whole cohort
were different to the subgroup of patients whose pri-
mary diagnosis was cancer.
In addition to risk, absolute rates of VTE were deter-
mined to account for varying length of survival by type of
cancer. The rates were presented by cancer site and timing
of VTE event in relation to hospitalisation: during hospi-
talisation or 6 months post-discharge. Person-time at risk
commenced at the time of index date or time from dis-
charge for each respective group. Patients were followed
up until they developed a VTE event, died, 6 months post-
discharge, or 31 October 2012 (last data collection date),
whichever was earliest. Rates were calculated as the
number of first VTE events divided by person-time (per
1000 person-years). VTE events concurrent with start
of follow-up were excluded (as these patients did not
contribute person-time years). All data management and
statistical analysis were performed using Stata 12 (Stata-




A total of 3,558,680 patients were identified with a hospital
admission for cancer between 1998 and 2012. The median
age at index date was 70 (IQR 59.6, 78.7) years. Of these
patients, 108,770 (3.06 %) had a VTE anytime between
index date and up to 6 months from discharge; just under
two-thirds of these (n = 66,954; 61.6 %) had their first VTE
during the hospitalisation for cancer (Table 1). Of the
155,650 patients who had aVTE any time during the study
period, n = 70, 725 (45.4 %) had a PE and n = 84,925
(54.6 %) had a DVT as their first VTE event. There were
6235 (4 %) patients who died from their VTE during the
study period and the median (interquartile range) follow-
up time was 1.6 (0.31, 4.40) years.
Risk of first VTE by cancer site and timing from index date
For the majority of cancers, the risk of VTE during hos-
pitalisation was higher than in the first 6 months post-
discharge (1.88 vs. 1.42 % respectively, overall) (Table 2).
The cancer sites with the highest proportion of VTE
events during initial hospitalisation for cancer were pan-
creatic (4.89 %), ovarian (4.01 %) and liver (3.84 %). In
contrast, VTE occurred in less than 0.5 % of patients
with malignant melanoma, oral and laryngeal cancer. Of
the 2,943,792 patients alive at discharge and without a
prior VTE event, the three cancer sites with the highest
risk of a VTE within 6 months were pancreatic (3.66 %),
oesophagus (2.98 %) and stomach (2.84 %).
Risk of VTE by age and timing from index date
For all cancers combined, the risk increased from 1.4 %
in those less than 60 years to 2.3 % in those over 80 years
(Table 3). However, for the cancers we considered with a
poor prognosis (lung, liver and pancreatic), the risk of
VTE during hospitalisation decreased with age.
Trends of VTE by calendar year
Figures 1 and 2 display the risk of VTE during hospitalisa-
tion and within 6 months of discharge, respectively, by
year of index date. With respect to the risk during hospi-
talisation, the trends varied by cancer site. Overall, the risk
decreased with time, especially for breast and prostate
cancer. In contrast, for lung cancer, the risk of VTE in-
creased between 1998 and 2008. With respect to the risk
of VTE as a re-admission, there was an overall increase
over the calendar period. The increase was relatively small
for breast and prostate but significant for lung and bowel,
increasing twofold for lung and just over 50 % for bowel
from 1998 to 2011.
Trends of VTE by calendar year stratified by length of stay
When stratified by hospital duration, the reduction of VTE
over time is less pronounced for breast cancer but the rise
amongst lung cancer patients still remains (Additional
file 1: Figure S1). Trends by length of stay were similar
between the overall cohort (Additional file 1: Figure S1)
Table 1 Patient characteristics









Mean (SD) 68.2 (14.3)
Median (IQR) 70 (59.6, 78.7)
Follow-up time (years)
Total 12,028,985
Median (IQR) 1.70 (0.33, 5.46)
First VTE event
During hospitalisation 66,954 43.02b
Within 6 months following discharge 41,816 26.87b
Beyond 6 months following discharge 46,880 30.12b
Entire study 155,650
SD standard deviation, IQR interquartile range
aUnless otherwise stated
bTotal number of patients who had a VTE during the entire study
Ratib et al. Journal of Hematology & Oncology  (2016) 9:60 Page 3 of 9
Table 2 First VTE event (%) stratified by cancer site and timing of event, up to 6 months from discharge
First VTE event During hospitalisation Within 6 months following discharge Total
Cancer site No. of people No. with VTE % No. of people alive
at discharge & no
previous VTE
No. with VTE % No. with VTE %
Breast 525,053 4843 0.92 485,009 3643 0.75 525,053 8486 1.62
Lung 395,671 9808 2.48 278,182 6436 2.31 395,671 16,244 4.11
Bowel 432,308 7369 1.70 364,489 5635 1.55 432,308 13,004 3.01
Prostate 384,078 5876 1.53 335,231 2191 0.65 384,078 8067 2.10
Non-Hodgkin lymphoma 134,096 2979 2.22 113,989 2155 1.89 134,096 5134 3.83
Malignant melanoma 86,496 318 0.37 82,445 155 0.19 86,496 473 0.55
Bladder 241,152 2057 0.85 217,217 1547 0.71 241,152 3604 1.49
Kidney 73,273 2229 3.04 60,755 724 1.19 73,273 2953 4.03
Oesophageal 98,668 1395 1.41 79,812 2379 2.98 98,668 3774 3.82
Stomach 86,454 2044 2.36 66,314 1886 2.84 86,454 3930 4.55
Pancreatic 78,579 3846 4.89 52,296 1915 3.66 78,579 5761 7.33
Leukaemia 108,405 1913 1.76 86,648 928 1.07 108,405 2841 2.62
Uterus 74,346 1113 1.50 68,516 705 1.03 74,346 1818 2.45
Ovarian 70,613 2834 4.01 57,162 1314 2.30 70,613 4148 5.87
Oral 69,827 301 0.43 62,784 378 0.60 69,827 679 0.97
Brain 69,362 1545 2.23 55,107 1353 2.46 69,362 2898 4.18
Multiple myeloma 59,610 1058 1.77 48,944 1033 2.11 59,610 2091 3.51
Liver 52,242 2005 3.84 36,485 783 2.15 52,242 2788 5.34
Cervix 33,618 530 1.58 30,596 459 1.50 33,618 989 2.94
Laryngeal 25,918 127 0.49 22,879 86 0.38 25,918 213 0.82
Testicular 22,985 172 0.75 22,481 201 0.89 22,985 373 1.62
Bone/connective tissue 30,023 483 1.61 26,490 293 1.11 30,023 776 2.58
Thyroid 22,718 122 0.54 21,368 56 0.26 22,718 178 0.78
Mesothelioma 22,354 361 1.61 17,350 349 2.01 22,354 710 3.18
Other site 102,771 1792 1.74 87,853 1190 1.35 102,771 2982 2.90
Unknown 258,040 9834 3.81 163,390 4022 2.46 258,040 13,856 5.37
Total 3,558,660 66,954 1.88 2,943,792 41,816 1.42 3,558,660 108,770 3.06
Table 3 First VTE event (%) during hospitalisation stratified by cancer site and age-group
Age (years)
Cancer site <60 60–80 >80
During hospitalisation No. of people No. with VTE % No. of people No. with VTE % No. of people No. with VTE %
Breast 231,286 1166 0.50 220,311 2112 0.96 73,456 1565 2.13
Lung 60,594 1820 3.00 249,044 5775 2.32 86,033 2213 2.57
Bowel 76,305 984 1.29 247,306 4068 1.64 108,697 2317 2.13
Prostate 32,460 255 0.79 239,913 3516 1.47 111,705 2105 1.88
Ovarian 25,834 740 2.86 34,245 1527 4.46 10,534 567 5.38
Pancreatic 13,278 700 5.27 44,386 2259 5.09 20,915 887 4.24
Liver 11,020 514 4.66 28,717 1101 3.83 12,505 390 3.12
All cancers 915,676 12,787 1.40 1,879,373 36,692 1.95 763,631 17,475 2.29
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and the subgroup of patients whose primary diagnosis
was cancer (Additional file 2: Figure S2).
Risk of VTE by chemotherapy
Of the study population, a total of 719,257 patients (20.2 %)
received inpatient chemotherapy during the study period
and the median time from index date to chemotherapy
was 46 (IQR 16, 104) days. The number of people who re-
ceived chemotherapy during their initial hospitalisation
was 250,638 (7 %). Of those who were discharged without
a VTE, and followed-up for up to 6 months, 22.7 % re-
ceived chemotherapy (Table 4). For these patients, the odds
ratio of VTE in those who underwent chemotherapy com-
pared to those who did not was 1.75 (95 % CI 1.72, 1.79).
The cancer sites associated with the highest risk of VTE
within 6 months from discharge, if chemotherapy was
undertaken, were pancreatic (5.2 %), stomach (4.87 %) and
oesophageal (4.67 %). The cancer sites with the highest
risk of VTE amongst patients not receiving chemotherapy
were pancreatic (3.20 %), brain (2.52 %) and ovarian
(2.43 %). For all cancer sites, except brain, ovarian, mul-
tiple myeloma and oral cancer, the proportion of chemo-
therapy patients who had a VTE event was statistically
significantly higher than those who did not undergo treat-
ment (p < 0.05 for all instances).
VTE rates by cancer site and timing from index date
For all cancer sites, the absolute rate of VTE was higher
during hospitalisation compared with rates in the first
6 months following discharge. In the first 6 months follow-
ing discharge, the cancer sites associated with the highest
rates were pancreatic (11.9 per 1000 person-years; CI
11.3–12.4), oesophageal (7.8; CI 7.4–8.1) and lung (6.8;
CI 6.7–7.0). The overall rate of VTE was 3.34 per 1000































































Fig. 2 Percentage of patients with first VTE within 6 months following discharge by year of cancer diagnosis
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Discussion
Main findings
We found that more people developed VTE in their ini-
tial hospitalisation than in the subsequent 6 months, for
most cancer types. Regardless of how we assessed VTE,
pancreatic cancer was associated with the highest risk of
VTE of all measured cancer types, both overall and spe-
cifically amongst those who underwent chemotherapy.
The overall risk of VTE in people hospitalised for cancer
was 3.06 % and overall varied from 1.88 % during hospi-
talisation to 1.42 % within 6 months from discharge; in
those with pancreatic cancer, the equivalent risk was
4.89 and 3.66 %, respectively. For cancer types with a
poor prognosis (e.g., lung), there was a negative associ-
ation between age and risk of VTE. For most cancer
types, the risk of VTE within 6 months from discharge
was higher amongst those who received chemotherapy
than those who did not. Compared with previous work,
we found important differences in time trends depending
on whether VTE was assessed during the initial hospital-
isation or in the ensuing 6 months. In particular, re-
admission rates for VTE from 1998 to 2011, increased by
twofold in patients with lung cancer and 50 % in those
with bowel cancer.
Strengths and limitations
This is the first study to describe the risk of VTE in a hos-
pitalised cancer population in the UK and is one of the
largest studies worldwide on this topic. The large sample
size gives precise risk estimates stratified by cancer type,
including those of lower prevalence. As the HES database
incorporates all inpatient and day case hospital admissions
taking place in England, our results are nationally general-
isable. Moreover, we have been able to distinguish VTE
events which were recorded during the cancer admission
from those recorded in re-admissions over the subsequent
Table 4 First VTE event within 6 months from discharge (%) stratified by cancer site and chemotherapy
Cancer site No. of people alive and no
VTE during hospitalisation
Chemotherapy VTE % No chemotherapy VTE %
Breast 485,009 138,776 1871 1.35 346,233 1772 0.51
Lung 278,182 71,155 2389 3.36 207,027 4047 1.95
Bowel 364,489 96,577 1853 1.92 267,912 3782 1.41
Prostate 335,231 17,687 180 1.02 317,544 2011 0.63
Non-Hodgkin lymphoma 113,989 60,495 1165 1.93 53,494 990 1.85
Malignant melanoma 82,445 4088 20 0.49 78,357 135 0.17
Bladder 217,217 32,418 291 0.90 184,799 1256 0.68
Kidney 60,755 4458 61 1.37 56,297 663 1.18
Oesophageal 79,812 22,786 1063 4.67 57,026 1316 2.31
Stomach 66,314 14,916 726 4.87 51,398 1160 2.26
Pancreatic 52,296 12,015 625 5.20 40,281 1290 3.20
Leukaemia 86,648 23,957 287 1.20 62,691 641 1.02
Uterus 68,516 7615 146 1.92 60,901 559 0.92
Ovarian 57,162 28,259 613 2.17 28,903 701 2.43
Oral 62,784 12,080 114 0.94 50,704 264 0.52
Brain 55,107 6726 135 2.01 48,381 1218 2.52
Multiple myeloma 48,944 18,175 348 1.91 30,769 685 2.23
Liver 36,485 5228 155 2.96 31,257 628 2.01
Cervix 30,596 7651 177 2.31 22,945 282 1.23
Laryngeal 22,879 2711 15 0.55 20,168 71 0.35
Testicular 22,481 9119 103 1.13 13,362 98 0.73
Bone/connective tissue 26,490 4231 78 1.84 22,259 215 0.97
Thyroid 21,368 717 3 0.42 20,651 53 0.26
Mesothelioma 17,350 4908 120 2.44 12,442 229 1.84
Other site 87,853 36,920 476 1.30 50,933 714 1.40
Unknown 163,390 25,095 1128 4.49 138,295 2894 2.09
Total 2,943,792 668,763 14,142 2.11 2,275,029 27,674 1.22
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6 months, providing novel information that can be used in
a clinical setting.
Our study has several weaknesses. First, is the lack of
detail in HES to establish whether VTE is the cause or
consequence of hospitalisation when assessing VTE as
baseline. This is a limitation inherent in all hospital-based
studies using discharge notes, as primary diagnosis is not
necessarily the reason for hospitalisation. Second is the re-
liability of the diagnostic coding for VTE in HES. This is
in terms of sensitivity, as not all VTE events may be re-
corded in secondary care, as well as specificity, as data to
support a VTE diagnosis, such as evidence of anticoagu-
lant treatment, are not available in HES. As we did not
have access to outpatient data, and given that the majority
of cancer-associated VTE is diagnosed and managed as an
outpatient [20], our estimates of the risk of VTE post-
discharge are most probably underestimated. Thus, the
true burden of VTE in hospitalised cancer patients post-
discharge may be greater than we report. However, as VTE
events occurring during an inpatient admission would be
fully recorded, we do not believe that our rates of VTE
during hospitalisation will be underestimated. Third, our
study is only able to assess the risk of VTE in people who
are hospitalised for cancer, so these results cannot be
applied to patients not hospitalised for their cancer (for in-
stance those who die without ever being hospitalised).
Similar to previous studies, we lack information on po-
tential confounders such as stage of disease and comor-
bidity which have been shown to be associated with risk
of VTE. These variables could explain why patients with
certain cancer types, and those undergoing chemother-
apy, have a higher risk of VTE than others [14, 20]. Fi-
nally, as in the case of other studies, it is likely that we
have underestimated the number of people receiving
chemotherapy as we have only included therapy during
hospital admission.
Comparison with other studies
This current study is consistent with the findings of previ-
ous work, that pancreatic cancer is associated with the
highest risk of VTE amongst patients hospitalised for can-
cer [16–18]. With respect to the risk of VTE during hospi-
talisation, Stein et al. [17] found a similar finding of 2 %
risk of VTE in patients hospitalised for cancer between
1979 and 1999. However, a US-based cohort study by
Khorana et al. [18] reported a 4.1 % overall risk of VTE
during hospitalisation, almost double the risk we report.
The risk of VTE may be higher in the USA compared to
the UK due to true population differences or different case
ascertainment and/or use of prophylaxis. The studies by
Levitan et al. [15] and a separate US study specifically in-
cluding patients with neutropenia (Khorana et al. [16])
both demonstrated that the risk of re-admission for VTE
is smaller than during initial hospitalisation, similar to this
current study This could be a result of comorbidities, in-
fections, lack of mobility or the effect of various treat-
ments during hospitalisation, which are all associated with
risk of VTE or the aforementioned potential for under re-
cording of VTE events occurring post-discharge [21–26].
With respect to the association between age and risk of
VTE in cancer patients, there are inconsistent findings in
the literature [16, 18, 27]. We have found, in general, that
risk of VTE increases with age during initial hospitalisa-
tion, apart from cancers with a poor prognosis. The former
could be due to increasing baseline risk of VTE with age.
The latter finding could be due to older patients with a
poor prognosis being more likely to die before having a
VTE than younger patients.
Regarding the effect of treatment on the risk of VTE, the
study by Khorana et al. [18] is the only previous hospital-
based study to examine the association between VTE event
and chemotherapy and also found the risk of VTE was
higher amongst patients who underwent chemotherapy,
than those who did not. However, because the study was
not prospective, they were unable to explore the risk of re-
admission of VTE, neither were results for chemotherapy
stratified by cancer type. In our study, we included epi-
sodes of chemotherapy delivered in subsequent day
case admissions and as such would have captured this
information more comprehensively. This could explain
why we found a higher proportion of patients undergo-
ing chemotherapy [18].
To our knowledge, only one study has stratified rates by
cancer site and demonstrated how the increase in rates
over calendar period was higher in those with a greater
rate of VTE [27]. In addition to this, we have demon-
strated that the trends in VTE vary not only by cancer site
but whether the VTE event occurred during hospitalisa-
tion (adjusting for length of stay) or following discharge,
with subsequent VTE in patients with cancers of the lung
having increased markedly over the 14-year study period.
Clinical implications
Given that our study and others highlight the varying risk
of VTE by cancer site and the higher risk in hospital com-
pared to post-discharge, careful consideration of the pa-
tients that would and would not benefit from prophylaxis
following hospitalisation is required. For example, young
patients with malignant melanoma may experience a net
harm from taking in-hospital prophylaxis whereas young
patients with pancreatic, lung or liver cancer may benefit.
One could argue, however, that for patients with pancre-
atic cancer, who are at such advanced disease stage and in
poor health in general, that prevention of VTE may not be
cost effective as they are likely to die short term for other
reasons. The relatively low risk of VTE in patients with
myeloma could reflect clinicians’ use of routine prophy-
laxis during chemotherapy as an outpatient and reflects
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results from other inpatient studies which report VTE
rates in myeloma which are similar to the average for all
cancer patients) [16, 18].
Our work adds to ongoing research investigating the as-
sociation of chemotherapy with the development of VTE
in patients with cancer. Such an association has been
shown in several studies [2, 28–31]. For example, in one
population-based case-control study, patients receiving
chemotherapy had a higher odds ratio for the development
of VTE (6.5) than those not receiving chemotherapy (4.1),
when compared with patients without cancer [2]. Our
group’s recent work on VTE in breast cancer showed the
risk of VTE was tenfold when chemotherapy was treated
as a time-varying covariate [31]. Due to limitations of the
data in this current study, we have only been able to
crudely analyse the effect of chemotherapy on risk of VTE.
Khorana et al. [32] published a risk assessment model to
estimate the risk of VTE in patients with cancer receiving
chemotherapy (4066 patients) which has set the stage for
randomised clinical trials in this area. In this risk model,
cancers of the stomach and pancreas were classed as very
high risk. Such a classification was supported by data from
the sub-group of patients in our study who underwent
chemotherapy (which took place an average of 46 days
into the 6 month interval), with a high VTE risk (>4 %)
also occurring amongst people with oesophageal cancer.
Such information could be used to influence the introduc-
tion of chemotherapy as a risk factor into some guidelines
for specific sub-groups of patients, as has been suggested
by the National Comprehensive Cancer Network [33].
We have demonstrated that trends of VTE over time
vary considerably by cancer site. For example, in patients
with lung cancer, the risk of VTE during hospitalisation
doubled between 1998 and 2008 (even after adjusting for
length of hospital stay), whereas it fell or only slightly in-
creased for all other cancers. This rise may be explained by
greater ascertainment by computerised tomography (CT)
scan rather than a real rise. Patients with lung cancer are
most likely to get follow-up CT scans than patients with
other cancers, and there is increasing CT availability and
increasing resolution of scans in the UK.
Conclusions
This is the first hospital-based study to report the risk of
VTE amongst patients with cancer in the UK. When con-
sidering clinical guidelines for inpatients, cancer site may
need to be taken into account, especially as the risk varies
from 0.37 % (malignant melanoma) to 4.89 % (pancreas).
There could be more of a focus on early prophylactic use
amongst the high-risk cancers immediately following hos-
pitalisation, especially amongst younger patients with pan-
creatic cancer, and consideration of chemotherapy, as a
potential risk factor, in future clinical decision-making
may be required.
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